Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

Authors
Publication date
1 January 2021
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Kölner UniversitätsPublikationsServer

      redirect
      oaioai:USBKOELN.ub.uni-koeln.de:5...
      Last time updated on 16/05/2022